Prism Biolab Co., Ltd. (206A) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Prism Biolab Co., Ltd. (206A:JPX), powered by AI.

Current Price
¥135
Sector
Healthcare
What is the Prism Biolab Co., Ltd. stock price forecast?

Prism Biolab Co., Ltd. is currently trading at ¥135. View real-time AI analysis on Alpha Lenz.

What is Prism Biolab Co., Ltd. insider trading activity?

View the latest insider trading data for Prism Biolab Co., Ltd. on Alpha Lenz.

What is Prism Biolab Co., Ltd.'s P/E ratio?

View Prism Biolab Co., Ltd.'s valuation metrics on Alpha Lenz.

Prism Biolab Co., Ltd.

JPX · 206A
¥135+2(+1.50%)Market closedJPX regular session 09:00–15:00 JST
Ask about Prism Biolab Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Prism Biolab Co., Ltd.'s ROE is -26.8%. Explore profitability and growth together.

Ask for details

Company Overview

Prism Biolab Co., Ltd. is a pioneering biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Specializing in regenerative medicine and pharmaceutical research, the company aims to address unmet medical needs through cutting-edge biotechnology. Prism Biolab's notable work includes the development of proprietary compounds and technologies that contribute to advancements in tissue engineering and biologics. The firm is heavily engaged with sectors such as healthcare and pharmaceuticals, serving a broad spectrum of clients that range from hospitals to academic research institutions. Prism Biolab Co., Ltd. is significant in the financial market as it represents the intersection of medical innovation and investment opportunities. The company's work not only fosters potential breakthroughs in treatment methodologies but also drives growth within the biotech industry, underlining its critical role in advancing healthcare technologies worldwide.

CEOMr. Dai Takehara
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
¥677,330,000Revenue
0.00Shares Out
0Employees

Margins

39.83%Gross
-102.09%EBITDA
-114.34%Operating
-122.73%Pre-Tax
-123.09%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

6.90%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-21.90%ROA
-26.84%ROE
-20.34%ROIC

Financial Health

¥2,915,572,000Cash & Cash Equivalents
¥-2,538,709,000Net Debt
13.91%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Prism Biolab Co., Ltd. (ticker: 206A) is a company listed on JPX in the Healthcare sector (Biotechnology).

The current price is 135 with a P/E ratio of -x and P/B of -x.

ROE is -26.84% and operating margin is -114.34%. Annual revenue is $677M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Prism Biolab Co., Ltd. (206A) Stock Forecast 2026 ¥135 — Price, Financials & Analyst Targets | Alpha Lenz